Amgen will invest over $600 million in a new science and innovation center at its Thousand Oaks, Calif., headquarters, extending a string of recent U.S. manufacturing expansions.
Construction on the facility is set to begin this quarter. The building will bring together researchers, engineers, and scientists from across disciplines and include advanced automation and digital systems aimed at accelerating the discovery of new therapeutics.
“This new center will empower our scientists with the tools and collaborative environment they need to shape the next era of scientific discovery and advance medicines that improve human health,” Robert Bradway, Amgen’s chairman and CEO, said in a statement.
The investment follows a $900 million expansion of Amgen’s biomanufacturing plant in New Albany, Ohio, announced earlier this year. That project, which builds on a facility the company opened in 2024, is expected to add 350 jobs and bring total employment at the site to about 750.
In December, the company committed another $1 billion to establish a second drug substance manufacturing facility in Holly Springs, N.C., bringing its overall investment in that location to more than $1.5 billion. Together with its existing facility there, Amgen expects to add 370 jobs in the region.
Amgen’s investments reflect a wider pharmaceutical push to pour billions of dollars into U.S. manufacturing, R&D, and next-generation production.
